BIO-TECHNOLOGY GENERAL CORP. COMMENCES LAWSUIT AGAINST GENENTECH AND ITS LAWYERS SEEKING DECLARATORY JUDGMENTS AGAINST GENENTECH AND DAMAGES IN EXCESS OF $100 MILLION.ISELIN, N.J.--(BUSINESS WIRE)--January 9, 1995--Bio-Technology General Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BTGC BTGC Bio-Technology General (stock symbol) BTGC Bukit Tinggi Golf Club (Malaysia) ) today announced that it has commenced a lawsuit in New York Federal Court against Genentech and its lawyers. BTG's complaint against Genentech and its lawyers, Rogers & Wells and John E. Kidd, seeks the following relief: 1. Declaratory judgments that three Genentech patents are invalid, not infringed and unenforceable against BTG BTG BIT (Built-In Test) Target Generator BTG Bridging the Gap BTG British Technology Group BtG Betreuungsgesetz (Germany) BTG Biomass Technology Group BV BTG Begbies Traynor Group . 2. Judgment that Genentech has violated the Sherman Antitrust Act Sherman Antitrust Act, 1890, first measure passed by the U.S. Congress to prohibit trusts; it was named for Senator John Sherman. Prior to its enactment, various states had passed similar laws, but they were limited to intrastate businesses. , the Lanhan Act, and the Civil Rights Act. 3. Judgment that Genentech and its counsel have committed wrongful acts including malicious prosecution, abuse of process and unfair competition. 4. Compensatory damages in an amount exceeding $100 million. 5. An order enjoining en·join tr.v. en·joined, en·join·ing, en·joins 1. To direct or impose with authority and emphasis. 2. To prohibit or forbid. See Synonyms at forbid. Genentech from continuing to prosecute legal actions against BTG. "The recent dismissal of Genentech's action against BTG by an Administrative Judge of the International Trade Commission because of Genentech's sanctionable misconduct clearly demonstrates Genentech's intentions to attempt to preclude competition in the U.S. for genetically engineered human growth hormone human growth hormone (HGH): see growth hormone. through use of harassing tactics, malicious prosecution, and denial of due process," stated BTG's president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Sim Fass. "It is time that such Genentech activities be halted. We are hopeful that the lawsuit we are initiating today against Genentech and its lawyers will achieve this end. We never have infringed any valid Genentech patent claim and are convinced that our position will be sustained when a full record is before a Court. We are continuing our efforts to gain U.S. Food and Drug Administration approval to market Bio-Tropin(TM), our human growth hormone." Bio-Technology General Corp. develops, manufactures and markets genetically engineered and other products for human healthcare. CONTACT: BIO-TECHNOLOGY GENERAL CORP.
Leah Berkovits, 908/632-8800
or
STRATEGIC GROWTH INTERNATIONAL
Don Weinberger, 212/826-9622
|
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion